BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Asahi Kasei Bioprocess and Axolabs Partner to Boost Oligonucleotide Therapy Development

Asahi Kasei Bioprocess (AKB), part of the Asahi Kasei Group, and Axolabs have announced a strategic partnership in the burgeoning field of oligonucleotide ...

April 12, 2024 | News

Nanoform Finland Plc Partners with CBC Co., Ltd. to Transform Japanese Pharmaceutical Industry with Nanotechnology

Nanoform Finland Plc ("Nanoform") announced a strategic partnership whereby CBC Co., Ltd. ("CBC"), will utilize its extensive experience in the Japan...

April 12, 2024 | News

ACROBiosystems Debuts 3D Organoid Solutions for Biotherapeutic Research

ACROBiosystems has been continuously rolling out a series of innovative organoid-related products. At a range of significant international events, includin...

April 11, 2024 | News

Eisai and Biogen Seek FDA Approval for Monthly Alzheimer's Treatment Dosing

Eisai Co., Ltd. and Biogen Inc. have taken a significant step forward in the fight against Alzheimer’s disease by submitting a Supplemental Biologics...

April 01, 2024 | News

Resonance Health Joins Forces with Micron, Inc. for Strategic Entry into Japan's Healthcare Sector

Resonance Health Ltd, listed on the Australian Securities Exchange (ASX) under the ticker RHT, has officially announced its strategic move into the Japanes...

March 28, 2024 | News

Takeda Receives FDA Approval for ICLUSIG as a First-Line Treatment in Ph+ ALL

Takeda Receives FDA Approval for ICLUSIG as a First-Line Treatment in Ph+ ALL Takeda Pharmaceutical Company Limited (TSE: 4502; NYSE: TAK) is plea...

March 25, 2024 | News

Takeda Achieves Groundbreaking FDA Approval for ICLUSIG® in Treating Newly Diagnosed Ph+ ALL Patients

This approval marks a pioneering step in treating adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) ALL, offering a combination th...

March 20, 2024 | News

Ajinomoto Bio-Pharma Services Sweeps CDMO Leadership Awards in Unprecedented Six-Category Win

Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, received CDMO Le...

March 13, 2024 | News

Ono Pharmaceutical Forms Strategic Alliance with Harvard University for Drug Discovery

Ono Pharmaceutical announced that it entered into a five-year, university-wide strategic research alliance agreement with Harvard University&nbs...

March 12, 2024 | News

Eisai Boosts Support for Alzheimer's Diagnosis with $15 Million Investment in C2N Diagnostics

Eisai Co., Ltd. announced a significant step forward in the fight against Alzheimer's disease (AD) today, with its U.S. subsidiary Eisai Inc. committing up...

March 07, 2024 | News

MGI Tech & Juntendo University: Transforming Care for Rare Disease Patients

While they are identified and addressed differently around the world, there are over known 6,000 rare diseases – characterized by a wide range of dis...

February 29, 2024 | News

Ono Pharmaceutical Partners with InveniAI to Revolutionize Drug Discovery Using AI

Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; "Ono") has announced a strategic partnership with the AI-driven company InveniAI...

February 22, 2024 | News

Japan Accelerates Approval Process for Groundbreaking Urothelial Cancer Treatment by Astellas

Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, "Astellas") announced that Japan's Ministry of Health, Labour a...

February 19, 2024 | News

Japan Becomes First in the World to Approve Dupixent® for Chronic Spontaneous Urticaria (CSU)

Approval based primarily on results from Phase 3 trial showing Dupixent significantly reduced itch compared to placebo CSU is the fifth appr...

February 17, 2024 | News

Stay Connected